個(gè)人簡(jiǎn)介：

Shirley Liu, PhD Chief Executive Officer Co-Founder Dr. Xiaole Shirley Liu co-founded GV20 Therapeutics in 2016 and became the CEO of GV20 in 2022. She was a Professor of Biostatistics and Computational Biology at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health and co-director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her computational biology work refined our understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors in different cancers. Dr. Liu is a highly cited researcher with a prodigious publication record that includes more than 200 papers published by her group, many in high-profile journals and highly cited. Shirley received the Sloan Research Fellowship (2008), has been a Breast Cancer Research Foundation Investigator (2017) and became a Fellow of ISCB (2019). In addition, she was recognized with the Benjamin Franklin Award for Open Access in the Life Sciences and the ISCB Innovator Award in 2020. Recently, she was selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.

公司簡(jiǎn)介：

由哈佛大學(xué)終身教授劉小樂(lè )Shirley Liu創(chuàng )立，是一家致力于通過(guò)應用基因組學(xué)、計算生物學(xué)、生物大數據和人工智能，來(lái)篩選癌癥藥物的有效靶點(diǎn)和開(kāi)發(fā)全人源抗體藥物的first-in-class新藥研發(fā)公司。?

公司已擁有全套自主知識產(chǎn)權的“Atlas全基因組靶點(diǎn)篩選平臺”和“Phial AI抗體藥設計平臺”。其中Atlas平臺是中國首個(gè)基于功能基因組學(xué)的腫瘤新藥靶標篩選平臺，在腫瘤功能基因組學(xué)、癌癥免疫治療和生物大數據技術(shù)上具有國際領(lǐng)先優(yōu)勢。而尋百會(huì )Phial AI抗體藥設計平臺是世界上唯一一個(gè)可以基于靶點(diǎn)設計全新抗體序列的計算平臺，具有靶點(diǎn)覆蓋面廣、準確度高、研發(fā)周期短、功能性強以及成藥性好等優(yōu)點(diǎn)?；谶@兩大平臺，公司已有多條管線(xiàn)藥物處于臨床開(kāi)發(fā)的不同階段，并與全球大型制藥企業(yè)有多種合作。我們希望通過(guò)AI賦能制藥，能夠迅速開(kāi)發(fā)高效的抗腫瘤新藥，通過(guò)精準醫療徹底治愈癌癥！

公司官網(wǎng)：http://www.bioxbh.com/